K-7174

• Description :

  K-7174 is an orally active proteasome and GATA inhibitor. K-7174 is a cell adhesion inhibitor. K-7174 induces cell apoptosis. K-7174 shows antitumor activities, it can be used for the research of cancer[1][2][3].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Apoptosis; Proteasome

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Metabolic Enzyme/Protease

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Cancer; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/K-7174.html

• Purity :

  98.02

• Solubility :

  10 mM in DMSO

• Smiles :

  COC1=C(OC)C(OC)=CC(/C=C/CCCN2CCN(CCC/C=C/C3=CC(OC)=C(OC)C(OC)=C3)CCC2)=C1

• Molecular Formula :

  C33H48N2O6

• Molecular Weight :

  568.74

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Umetani M, et al. A novel cell adhesion inhibitor, K-7174, reduces the endothelial VCAM-1 induction by inflammatory cytokines, acting through the regulation of GATA. Biochem Biophys Res Commun. 2000 Jun 7;272 (2) :370-4.|[2]Imagawa S, et al. A GATA-specific inhibitor (K-7174) rescues anemia induced by IL-1beta, TNF-alpha, or L-NMMA. FASEB J. 2003 Sep;17 (12) :1742-4.|[3]Kikuchi J, et al. The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases. J Biol Chem. 2013 Aug 30;288 (35) :25593-602.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Citation 01 :

  Adv Healthc Mater. 2024 Jul;13 (18) :e2304439.|Adv Sci (Weinh) . 2025 Apr;12 (16) :e2404311.|Biochem Genet. 2024 Dec 16.|Brain Res. 2023 Feb 15:1801:148203.|FEBS Open Bio. 2020 Sep;10 (9) :1880-1890.|Growth Horm IGF Res. 2025 May 21:82:101659.|Research Square Preprint. 2020 Dec.|Adv Sci (Weinh) . 2025 Apr;12 (16) :e2404311.|Biomaterials. 2021 Aug:275:120967.|bioRxiv. 2019 Sep.|Cell Rep Med. 2022 Mar 15;3 (3) :100561.|Department of Molecular Medicine and Biopharmaceutical Sciences. 2020 May.|FASEB J. 2020 Mar;34 (3) :4462-4481.|J Assist Reprod Genet. 2024 Oct;41 (10) :2759-2770.|J Clin Invest. 2024 Aug 15:e175023.|Sci Adv. 2025 Apr 11;11 (15) :eadk6989.

• CAS Number :

  [191089-59-5]